Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.
NB: Council approval does not guarantee that a concept will become an initiative.
Table of Contents
Fiscal Year 2018 Concepts
- Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics
- HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations
- HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure Through Clinical Research
- In Vitro and Animal Model Studies on HBV/HIV Co-Infection
Fiscal Year 2018 Small Business Innovation Research (SBIR) Contract Solicitation Topic
Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics
For the published program announcements, see the May 12, 2017 Guide announcements,Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R01)and Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R21).
HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations
For the published program announcements, see the May 17, 2017 Guide announcements, HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R01) and HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R21).
HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure Through Clinical Research
For the published program announcements, see the May 12, 2017 Guide announcements, HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research (R01)and HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research (R21).
In Vitro and Animal Model Studies on HBV/HIV Co-Infection
For the published program announcements, see the May 12, 2017 Guide announcements, In Vitroand Animal Model Studies on HBV/HIV Co-Infection (R01) and In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R21).
Methods To Increase Yields of HIV Envelope Protein Vaccine Manufacturing Through Cell Substrate Modifications or Through Novel Up- or Down-Stream Process Development Technologies
For the published request for proposals, see the July 18, 2017 Solicitation of NIH and CDC for SBIR Contract Proposals.